04 September 2010
Keywords: Sanofi-Aventis, Regeneron, Research collaboration, Licensing, Monoclonal antibodies
Article | 11 November 2009
France’s Sanofi-Aventis and USA-based Regeneron Pharmaceutical have entered into an agreement to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies through 2017, which would cost the French drug major over $1 billion over the eight years to expand its foot-print in biotechnology.
Under the extended deal, Sanofi will increase its annual funding commitment from $100 million a year to $160 million beginning 2010 and has an option to extend the program for up to an additional three years. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.